BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 16869749)

  • 1. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
    Kaelin WG
    Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of VHL gene mutation in human cancer.
    Kim WY; Kaelin WG
    J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
    Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
    J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The von Hippel-Lindau tumor suppressor gene.
    Kondo K; Kaelin WG
    Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
    Sufan RI; Jewett MA; Ohh M
    Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype-phenotype correlations, and retinal function and structure in von Hippel-Lindau disease.
    Wittström E; Nordling M; Andréasson S
    Ophthalmic Genet; 2014 Jun; 35(2):91-106. PubMed ID: 24555745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Von Hippel-Lindau disease.
    Kaelin WG
    Annu Rev Pathol; 2007; 2():145-73. PubMed ID: 18039096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Genetics and angiogenesis: the example of von Hippel-Lindau disease].
    Richard S; Ladroue C; Gad S; Giraud S; Gardie B;
    Bull Cancer; 2007 Jul; 94 Spec No():S170-9. PubMed ID: 17846002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HIF and other quandaries in VHL disease.
    Tarade D; Ohh M
    Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.
    Kaelin WG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):680s-684s. PubMed ID: 17255293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RSUME inhibits VHL and regulates its tumor suppressor function.
    Gerez J; Tedesco L; Bonfiglio JJ; Fuertes M; Barontini M; Silberstein S; Wu Y; Renner U; Páez-Pereda M; Holsboer F; Stalla GK; Arzt E
    Oncogene; 2015 Sep; 34(37):4855-66. PubMed ID: 25500545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The von hippel-lindau tumor suppressor protein: an update.
    Kaelin WG
    Methods Enzymol; 2007; 435():371-83. PubMed ID: 17998064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
    Moch H
    Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.